FinTechFunding

Immutep: Shares positive data from phase 2b AIPAC trial

Immutep Shares positive data from phase 2b AIPAC trial

  • Immutep (IMM) sees a significant increase in innate and adaptive immune response biomarkers in its phase IIb AIPAC trial
  • The trial evaluated efti combined with paclitaxel chemotherapy compared to a placebo group in 227 patients with HER2-negative/HR-positive metastatic breast cancer
  • IMM says the higher immune response in efti patients compared to placebo patients confirms efti is activating the immune system and improving overall survival
  • The company is a globally active biotechnology company that is a leader in developing LAG-3 related immunotherapeutic products
  • The company is trading 7.58 per cent higher at 35.5 cents
Previous article
Intigriti: Raises Over €21.13M in Series B Funding
Next article
Elixir Energy: Completes Tim-2 well in Mongolia
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Visa and TikTok Launch Creator Card, Enhancing Monetization for Influencers

New financial tool aims to streamline earnings for content creators.Highlights: Visa and TikTok have launched the new Creator...
FinTech

Nium and Coinbase Strengthen Global Stablecoin Settlement Partnership

The collaboration aims to enhance cross-border payments using stablecoins.Highlights: Nium partners with Coinbase to optimize stablecoin settlements.The collaboration...
FinTech

FCA Announces Second Cohort for AI Live Testing Initiative

New phase aims to improve integration of AI in financial services.Highlights: FCA launches second cohort for AI live...
FinTech

Cab Payments Strengthens Case Against Helios Blocking Takeover Bid

Cab Payments contests Helios Investment's actions regarding merger talks.Highlights: Cab Payments accuses Helios of blocking a crucial takeover...